Autoimmune Encephalitis Clinical Trial
Official title:
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis: Open-lable, Randomised, Proof of Concept Study
Autoimmune encephalitis (AE) is an immune-mediated brain disorder characterized by varied clinical manifestations that correlate with specific types of antibodies.Typical symptoms include acute behavioral changes, psychosis, seizures, memory deficits, dyskinesias, speech impairments, and autonomic and respiratory dysregulation.While the majority of patients respond well to immunotherapeutic agents, a significant proportion remains resistant to initial and secondary-line immunotherapies.Minocycline, a semisynthetic tetracycline, is notably used for the central nervous system due to its lipophilic characteristics and its capacity to penetrate the blood-brain barrier. While the primary neuroprotective focus of minocycline in the central nervous system remains unknown, the primary effects of minocycline include the inhibition of microglial activation, mitigation of apoptosis, and reduction in reactive oxygen species generation.Protective effect has been observed in hypoxic injury, ischemic stroke, amyotrophic lateral sclerosis, traumatic spinal cord injury, multiple sclerosis, Parkinson's disease, and Huntington's disease.Can minocycline offer a protective role in AE? Consequently, we proposed a randomized, controlled trial to investigate the efficacy of minocycline in AE.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | December 2028 |
Est. primary completion date | May 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Diagnosis of definite autoimmune encephalitis(Graus et al 2016.) 2. Age = 18 years 3. Acute or subacute onset (rapid progression of less than 3 months) 4. Reasonable exclusion of alternative causes 5. Written informed consent Exclusion Criteria: 1. Known allergy to tetracycline antibiotics. 2. Pregnant women. 3. Uncontrolled serious concomitant illness. 4. Known chronic kidney disease stages 3b-5. 5. Moderate liver disease (see Child-Pugh for Classification of Severity of Liver Disease). 6. history of cognitive impairment |
Country | Name | City | State |
---|---|---|---|
China | Xijing Hospital | Xi'an |
Lead Sponsor | Collaborator |
---|---|
Xijing Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | number of participants with medical laboratory results | medical laboratory results at admission | at admission | |
Other | medical imaging data | medical imaging data at onset | 3 months | |
Primary | MoCA scores | The proportion of patients with MoCA scores =26 at 3 months after enrollment. | 3 months | |
Secondary | mRS scores | The proportion of patients with mRS scores =2 at discharge. | 1 month | |
Secondary | MoCA scores | The proportion of patients with MoCA scores =26 at discharge. | 1 month | |
Secondary | MMSE scores | The proportion of patients with MMSE scores =27 at discharge. | 1 month | |
Secondary | mRS scores | The proportion of patients with mRS scores =2 at 3 months. | at 3 months | |
Secondary | MMSE scores | The proportion of patients with MMSE scores =27 at 3 months. | at 3 months | |
Secondary | HAMA scores | HAMA scores at 3 months. | at 3 months | |
Secondary | HAMD scores | HAMD scores at 3 months. | at 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT05645185 -
Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
|
||
Not yet recruiting |
NCT04106596 -
HLA Analysis in Autoimmune Encephalitis and Related Disorders
|
||
Completed |
NCT04708626 -
Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
|
||
Not yet recruiting |
NCT05711563 -
Predicting and Monitoring Outcomes in Autoimmune Encephalitis
|
||
Completed |
NCT04175522 -
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
|
Phase 2 | |
Recruiting |
NCT03194815 -
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
|
Phase 2 | |
Recruiting |
NCT06079294 -
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
|
N/A | |
Not yet recruiting |
NCT03957616 -
Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
|
||
Completed |
NCT02905136 -
Mechanisms of Auto-immune Encephalitis
|
||
Recruiting |
NCT05280600 -
Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
|
||
Recruiting |
NCT06173076 -
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
|
||
Recruiting |
NCT03993262 -
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
|
Phase 2 | |
Recruiting |
NCT04372615 -
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
|
Phase 2 | |
Recruiting |
NCT05177939 -
Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis
|
Phase 3 | |
Active, not recruiting |
NCT06432803 -
Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
|
||
Recruiting |
NCT06019975 -
FDG-PET in the Diagnosis of Autoimmune Encephalitis
|
||
Completed |
NCT05783947 -
Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
|
||
Not yet recruiting |
NCT06456736 -
Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment
|
||
Completed |
NCT05825690 -
BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis
|